%PDF-1.3 %âãÏÓ 1 0 obj << /Type/ExtGState /OPM 1 >> endobj 2 0 obj << /SM 0.01 /Type/ExtGState /FL 1 >> endobj 3 0 obj << /OP true /Type/ExtGState >> endobj 4 0 obj << /OP false /Type/ExtGState >> endobj 5 0 obj << /Length 9343 >> stream /GS0 gs q 0 0.89 595 841 re W n 1 g 0 841.89 0 0 re f Q /GS1 gs q /GS2 gs 0 0 0 0 k 56.693 620.788 481.889 107.716 re f Q /GS2 gs q BT /F0 1 Tf 20 0 0 20 57.6927 712.5873 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (Primer En\237rezis Nokturna Tedavisinde Desmopressin )Tj 0 -1.1 TD (ile Tedavi Alternatiflerinin Kar\337\335la\337t\335r\335lmas\335 (*))Tj ET Q /GS3 gs /GS2 gs q BT /F0 1 Tf 10 0 0 10 57.6927 638.5873 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (M\237feret ERG\206VEN (**), A. Nurcan \205Z\206M\206ZTOPRAK (***), Kadir BABAO\332LU (****), )Tj 0 -1.3 TD (Metin D\205NMEZ (****))Tj ET 0 J 0 j 10 M []0 d 1 w 0 0 0 1 K 56.693 610.618 m 538.582 610.618 l S 0 0 0 0 k 56.693 405.669 226.771 192.9261 re f Q /GS3 gs /GS2 gs q BT /F0 1 Tf 9 0 0 9 157.5739 590.8821 Tm 0 Tr 0 0 0 1 k -0.0001 Tc <85>Tj 0.77794 0.00001 TD 0 Tc 0 Tw (ZET)Tj ET Q /GS3 gs /GS2 gs q BT /F1 1 Tf 9 0 1.91301 9 57.6927 570.8821 Tm 0 Tr 0 0 0 1 k 0 Tc 0.057 Tw (Bu \215al\335\337ma, desmopressinin primer en\237rezis nokturna tedavi-)Tj 0.23617 -1.11111 TD 0.007 Tc 0.118 Tw (sindeki etkinli\333ini ara\337t\335rmak ve desmopressin ile en uygun)Tj 0.23617 -1.11111 TD 0 Tc 0 Tw (tedavi yakla\337\335m\335n\335 belirlemek amac\335yla yap\335ld\335. )Tj 0.47235 -2.22223 TD 0.035 Tc 0.09 Tw (Primer en\237rezis nokturna tan\335s\335 alan ve ya\337lar\335 6 ila 14)Tj 0.23617 -1.11111 TD 0.005 Tc 0.12 Tw (aras\335nda de\333i\337en 27 k\335z, 28 erkek toplam 55 \215ocuk \215al\335\337ma)Tj 0.23618 -1.11113 TD 0 Tc 0.011 Tw (kapsam\335na al\335nd\335. Hastalar iki gruba ayr\335ld\335lar. Grup I\325e y\237k-)Tj 0.23617 -1.11111 TD 0.021 Tc 0.104 Tw (sek doz, k\335sa s\237reli (40 \265g, tek doz, ayl\335k), Grup II\325ye ise)Tj 0.23617 -1.11111 TD 0.026 Tc 0.099 Tw (d\237\337\237k doz, uzun s\237reli (20 \265g, tek doz, alt\335 ayl\335k) desmo-)Tj 0.23617 -1.11111 TD 0.005 Tc 0.12 Tw (pressin tedavi protokol\237 uyguland\335. Tedavi ile Grup I\325de %)Tj 0.23617 -1.11111 TD 0 Tc 0.076 Tw (60, Grup II\325de ise % 63 olumlu yan\335t al\335nd\335. Tedavi kesildik-)Tj 0.23617 -1.11111 TD 0.045 Tw (ten sonra n\237ks oran\335 ise s\335ras\335yla % 94 ve % 76 olarak belir)Tj 24.64187 0 TD (-)Tj -24.40569 -1.11112 TD 0 Tw (lendi.)Tj ET Q /GS3 gs /GS2 gs q BT /F2 1 Tf 9 0 1.91301 9 57.6927 410.8821 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (Anahtar kelimeler:)Tj ET Q /GS3 gs /GS2 gs q BT /F1 1 Tf 9 0 1.91301 9 130.6837 410.8821 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (En\237rezis, desmopressin)Tj ET 0 0 0 0 k 311.811 405.678 226.771 192.926 re f Q /GS3 gs /GS2 gs q BT /F0 1 Tf 9 0 0 9 401.2058 590.8915 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (SUMMARY)Tj -9.02515 -2.22222 TD -0.0001 Tc (A)Tj 0.97182 0 Td 0 Tc (Comparison of Two Approaches to the Treatment of)Tj 0.6107 -1.11112 TD (Primary Enuresis Nocturna with Desmopressin)Tj ET Q /GS3 gs /GS2 gs q BT /F1 1 Tf 9 0 1.91301 9 312.8108 540.8915 Tm 0 Tr 0 0 0 1 k 0 Tc 0.021 Tw (The aim of this study was to investigate the efficacy of desmo)Tj 24.64189 0.00001 TD (-)Tj -24.40572 -1.11112 TD 0.067 Tw (pressin in the management of primary enuresis nocturna and)Tj 0.23617 -1.11111 TD 0.094 Tw (to determine the best approach to the treatment with desmo-)Tj 0.23618 -1.11112 TD 0.119 Tw (pressin. 55 children ranging in age from 6 to 14 years with)Tj 0.23617 -1.11111 TD 0.105 Tw (primary enuresis nocturna (27 girls, 28 boys) were included)Tj 0.23617 -1.11111 TD 0.036 Tc 0.089 Tw (in the study. The patients were divided into two groups.)Tj 0.23617 -1.11111 TD 0.018 Tc 0.107 Tw (Desmopressin was applied to the Group I as a high dose,)Tj 0.23617 -1.11111 TD 0 Tc 0.087 Tw (short term (40 \265g, single dose, monthly) and to the Group II)Tj 0.23617 -1.11111 TD 0.09 Tw (as a low dose, long term (20 \265g, single dose, semi-annually))Tj 0.23617 -1.11111 TD 0.007 Tc 0.118 Tw (therapy. The response to the therapy was 60 % in Group I)Tj 0.23617 -1.11111 TD 0 Tc 0.001 Tw (and 63 % in Group II. The relapse rate after treatment was 94)Tj 0.23617 -1.11111 TD -0.0001 Tc (%)Tj 1.08283 0 Td 0 Tc 0 Tw (and 76 %, respectively.)Tj ET Q /GS3 gs /GS2 gs q BT /F2 1 Tf 9 0 0 9 312.8108 410.8915 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (Key words: )Tj ET Q /GS3 gs /GS2 gs q BT /F1 1 Tf 9 0 1.91301 9 356.3013 410.8915 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (Enuresis, desmopressin)Tj ET 0 J 0 j 10 M []0 d 1 w 0 0 0 1 K 56.693 146.5671 m 538.583 146.5671 l S 0 0 0 0 k 56.693 118.898 481.889 22 re f Q /GS3 gs /GS2 gs q BT /F3 1 Tf 9 0 0 9 57.6927 132.8514 Tm 0 Tr 0 0 0 1 k 0 Tc 0.104 Tw (XXI. Ortado\333u ve Akdeniz Pediatri Dernekleri Birli\333i kongresinde poster olarak sunulmu\337tur (24-27 Ekim 1993)*; SSK G\232ztepe)Tj 0 -1.11111 TD 0 Tw (E\333itim Hastanesi \202ocuk Sa\333l\335\333\335 ve Hastal\335klar\335 Klini\333i, \336ef Yard. Dr.**; Asist. Dr.***; Uz. Dr.****)Tj ET 0 J 0 j 10 M []0 d 1 w 0 0 0 1 K 56.693 748.731 m 538.582 748.731 l S 56.693 771.024 m 538.582 771.024 l S 0 0 0 0 k 56.693 151.3941 226.772 234.284 re f Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 57.6929 376.8479 Tm 0 Tr 0 0 0 1 k 0.017 Tc 0.108 Tw (\334drar kontrol\237n\237n olmas\335 gereken ya\337ta gece uykuda)Tj 0 -1.3 TD 0 Tc 0.109 Tw (istemsiz yata\333a i\337eme olarak tan\335mlanan en\237rezis nok-)Tj T* 0.018 Tw (turna, aile ve \215ocuk i\215in son derece s\335k\335nt\335 verici bir du-)Tj T* 0.076 Tw (rumdur. \202o\333u \215ocuk 3-4 ya\337lar\335nda mesane kontrol\237ne)Tj T* 0.001 Tc 0.124 Tw (sahip olur; 6 ya\337 civar\335nda % 10, 14 ya\337lar\335nda ise %)Tj T* 0 Tc 0.125 Tw (5\325lik bir grup hala en\237rezis nokturnadan yak\335n\335r. En\237-)Tj T* 0.11 Tw (rezis nokturna 11 ya\337a kadar erkek \215ocuklarda 2-3 kat)Tj T* 0.009 Tw (daha s\335k g\232r\237l\237rken, bu ya\337tan sonra oran k\335zlarda biraz)Tj T* 0.015 Tc 0.11 Tw (daha artmaktad\335r. Gece idrar kontrol\237n\237n tam olarak)Tj T* 0 Tc 0.097 Tw (kazan\335lmad\335\333\335 durumda primer en\237rezis, \215ocu\333un daha)Tj T* 0.041 Tw (\232nce en az 6 ay - 1 y\335l kuru kald\335ktan sonra idrar ka\215\335r-)Tj T* 0.026 Tw (maya ba\337lamas\335 ise sekonder en\237rezis olarak adland\335r\335l-)Tj T* 0.011 Tc 0.114 Tw (maktad\335r. \202al\335\337malar\335n \215o\333unda en\237rezis nokturnan\335n)Tj -0.0001 Tc (%)' 1.0828 0 Td 0 Tc 0 Tw (80\325inin primer oldu\333u bildirilmektedir.)Tj -1.0828 -2.6 TD 0.054 Tw (En\237rezis tedavisinde \215e\337itli y\232ntemler ve ila\215lar denen-)Tj 0 -1.3 TD 0.047 Tw (mi\337tir. Aileler, \215ocuk ve hekim taraf\335ndan en \215ok kabul)Tj T* 0.08 Tw (g\232ren, medikal tedavi olmu\337tur. Trisiklik antidepresan-)Tj ET 0 0 0 0 k 311.811 151.399 226.772 234.2831 re f BT /F3 1 Tf 10 0 0 10 312.811 376.8525 Tm 0 0 0 1 k 0.122 Tw (lar, antikolinerjikler ve desmopressin en s\335k kullan\335lan)Tj 0 -1.3 TD 0.025 Tw (ila\215lard\335r. Bu \215al\335\337mada, antidi\237retik hormonun sentetik)Tj T* 0.004 Tc 0.121 Tw (bir analo\333u olan desmopressinin primer en\237rezis nok-)Tj T* 0 Tc 0.002 Tw (turna tedavisindeki etkinli\333i ve en uygun tedavi yakla\337\335-)Tj T* 0 Tw (m\335 ara\337t\335r\335ld\335.)Tj ET Q /GS3 gs /GS2 gs q BT /F0 1 Tf 10 0 0 10 312.811 298.8526 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (MATERYAL ve METOD)Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 9 0 0 9 312.811 275.8525 Tm 0 Tr 0 0 0 1 k 0 Tc 0.049 Tw (\202al\335\337ma Nisan 91-A\333ustos 92 tarihleri aras\335nda SSK G\232ztepe)Tj 0 -1.11111 TD 0.005 Tw (E\333itim Hastanesi, \202ocuk Klini\333i poliklini\333ine gelen ve primer)Tj T* 0.077 Tw (enrezis nokturna tan\335s\335 alan \215ocuklarda yap\335ld\335. \202al\335\337ma kap-)Tj T* 0.005 Tc 0.12 Tw (sam\335na, ya\337lar\335 6-14 ya\337 aras\335nda de\333i\337en ve ya\337 ortalamas\335)Tj T* 0 Tc 0.125 Tw (9.18\2612.29 y\335l olan 27 k\335z, 28 erkek toplam 55 \215ocuk al\335nd\335.)Tj 0 -1.11111 TD 0.047 Tw (Bu \215ocuklar en\237rezis nokturnaya y\232nelik daha \232nce hi\215bir te-)Tj 0 -1.11111 TD 0.119 Tw (davi almam\335\337lard\335. Hastalar ya\337, cins, kilo ve boy \232zellikleri)Tj T* 0.004 Tc 0.121 Tw (benzer 30 ve 25 ki\337ilik iki gruba ayr\335ld\335. Grup I\325i olu\337turan)Tj T* 0.005 Tc 0.12 Tw (toplam 30 \215ocuk y\237ksek doz-k\335sa s\237reli (40 \265g-1 ay), Grup)Tj T* 0 Tc 0.007 Tw (II\325yi olu\337turan toplam 30 \215ocuk d\237\337\237k doz-uzun s\237reli \(20 \265g-)Tj 0 -1.11111 TD 0.029 Tc (6)Tj 0.90395 0 Td 0.096 Tw (ay\) desmopressin tedavisi ald\335. Desmopressin hastalara)Tj -0.90395 -1.11111 TD 0 Tc 0.085 Tw (intranazal olarak uyguland\335. Tedavi sonu\215lar\335 ki-kare testi ile)Tj T* 0 Tw (de\333erlendirildi.)Tj ET 0 0 0 0 k 56.693 753.403 481.89 13 re f Q /GS3 gs /GS2 gs q BT /F0 1 Tf 10 0 0 10 57.6929 757.5739 Tm 0 Tr 0 0 0 1 k 0.0999 Tc (K)Tj 0.87791 0.00001 TD 0.1 Tc 0 Tw (L\334N\334K ARA\336TIRMA)Tj ET Q /GS3 gs /GS2 gs q BT /F1 1 Tf 10 0 2.12557 10 493.1929 757.5739 Tm 0 Tr 0 0 0 1 k 0.0999 Tc (P)Tj 0.71087 0.00001 TD 0.1 Tc 0 Tw (ediatri)Tj ET 0 J 0 j 10 M []0 d 1 w 0 0 0 1 K 56.692 395.9301 m 538.582 395.9301 l S 0 0 0 0 k 56.693 788.3701 128.724 11 re f Q /GS3 gs /GS2 gs q BT /F1 1 Tf 8 0 1.70046 8 57.6929 792.4114 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (G\232ztepe T\335p Dergisi 18: 144-146, 2003)Tj ET 0 0 0 0 k 56.693 91.882 17.012 13 re f Q /GS3 gs /GS2 gs q BT /F0 1 Tf 10 0 0 10 57.6929 96.4236 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (144)Tj ET 0 0 0 0 k 471.088 787.6771 67.512 11.693 re f Q /GS3 gs /GS2 gs q BT /F0 1 Tf 9 0 0 9 472.0881 791.6577 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (ISSN 1300-526X)Tj ET Q endstream endobj 6 0 obj << /Length 14015 >> stream /GS0 gs q 0 0.89 595 841 re W n 1 g 0 841.89 0 0 re f Q /GS1 gs q /GS2 gs 0 0 0 0 k 56.693 356.024 226.772 400.827 re f Q /GS2 gs q BT /F0 1 Tf 10 0 0 10 57.6929 748.021 Tm 0 Tr 0 0 0 1 k -0.0001 Tc (B)Tj 0.66693 0.00001 TD 0 Tc 0 Tw (ULGULAR)Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 57.6929 722.0211 Tm 0 Tr 0 0 0 1 k -0.0001 Tc (H)Tj 0.72189 0.00001 TD 0 Tc 0.067 Tw (astalar\335m\335z\335n ya\337, cins ve tedavi \232zellikleri \232zellikleri)Tj -0.72189 -1.30001 TD 0.028 Tc 0.097 Tw (aras\335nda fark bulunmad\335 (Tablo 1). Primer en\237rezis)Tj 0 -1.3 TD 0 Tc 0.078 Tw (nokt\237rna tan\335s\335 alan hastalar aras\335nda \237rolojik, renal ve)Tj T* 0.125 Tw (n\232rolojik patolojisi olmayan 55 \215ocuk \215al\335\337maya dahil)Tj T* 0.002 Tw (edildi. Tedavi \232ncesinde grup I\325de 2 haftal\335k yatak \335slat-)Tj 0.0284 Tc (ma)' 1.65374 0 Td 0.028 Tc 0.097 Tw (say\335s\335 ortalama 10.87\2611.96 iken II.grupta 10.84)Tj -1.65374 -1.3 TD 0 Tc 0.032 Tw (\2611.75 olarak bulundu. Tedaviyi takiben 4 hafta s\237resin-)Tj T* 0.034 Tw (ce desmoperssine yan\335t haftal\335k yatak \335slatma say\335s\335 0-1)Tj T* 0.05 Tw (olacak \337ekilde belirlendi. Tedaviye yan\335t verme oran\335 I.)Tj T* 0.001 Tc 0.124 Tw (grupta % 63, II. grupta % 60 olarak bulundu. \334ki haf-)Tj T* 0 Tc 0.001 Tw (tal\335k yatak \335slatma say\335s\335 I. grupta ortalama 5.00\2612.1, II.)Tj T* 0.027 Tc 0.098 Tw (grupta ortalama 5.25\2612.4 idi. \334ki gup aras\335nda kuru)Tj T* 0.007 Tc 0.118 Tw (geceler bak\335m\335ndan ve tedaviye yan\335t verme oran\335nda)Tj T* 0 Tc 0.124 Tw (anlaml\335 istatiksel fark saptanmad\335. II. grupta iyi sonu\215)Tj T* 0.008 Tc 0.117 Tw (al\335nan hastalarda tedavi 5 ay daha uzat\335ld\335. Doz azal-)Tj 0 -1.30001 TD 0 Tc 0.105 Tw (t\335larak 6. ayda tedavi sonland\335r\335ld\335. Hastalar tedavi ke-)Tj 0 -1.3 TD 0.043 Tw (sildikten sonra 8 hafta boyunca izlendi. Bu izlem d\232ne-)Tj 0 -1.30001 TD 0.049 Tc 0.076 Tw (minde I. grupta 2, II. grupta 6 hastada daimi etki)Tj 0 -1.3 TD 0.017 Tc 0.108 Tw (g\232zlendi. Di\333er hastalarda ise eski al\335\337kanl\335\333a d\232n\237\337)Tj T* 0.004 Tc 0.121 Tw (saptand\335 (Tablo 2). Daimi etki a\215\335s\335ndan iki grup ara-)Tj T* 0.006 Tc 0.119 Tw (s\335nda anlaml\335 fark saptan\335rken, desmopressin ile uzun)Tj T* 0 Tc 0.034 Tw (s\237reli tedavinin daimi etki sa\333lanmas\335 bak\335m\335ndan daha)Tj T* 0 Tw (uygun oldu\333u g\232zlendi. )Tj ET Q /GS3 gs /GS2 gs q BT /F0 1 Tf 10 0 0 10 57.6929 411.0211 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (TARTI\336MA)Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 57.6929 386.021 Tm 0 Tr 0 0 0 1 k 0.006 Tc 0.119 Tw (En\237rezis nokt\237rna; idrar kontrol\237n\237n olmas\335 gerekti\333i)Tj 0 -1.3 TD 0.069 Tc 0.056 Tw (ya\337ta gece uykuda istemsiz yata\333a i\337eme olarak)Tj T* 0.009 Tc 0.116 Tw (tan\335mlan\335r. \202o\333u ara\337t\335rmac\335 nokt\237rnal en\237rezisin ne-)Tj ET 0 0 0 0 k 311.811 119.055 226.772 637.796 re f BT /F3 1 Tf 10 0 0 10 312.811 748.021 Tm 0 0 0 1 k -0.0001 Tc (d)Tj 0.49992 0.00001 TD 0 Tc 0.099 Tw (eni olarak genetik, geli\337imsel, organik ve psikososyal)Tj -0.49992 -1.30001 TD 0.013 Tw (fakt\232rlerin birarada oldu\333unu d\237\337\237nmektedir )Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 495.4946 737.6611 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw ((1))Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 504.8188 735.021 Tm 0 Tr 0 0 0 1 k 0 Tc (.)Tj 0.51326 0 Td 0.013 Tw (Bu ko-)Tj -19.71404 -1.3 TD -0.0001 Tc (n)Tj 0.4999 0.00001 TD 0 Tc 0.044 Tw (uda yap\335lan ara\337t\335rmalarda var\335lan ortak prensip; soru-)Tj -0.4999 -1.30001 TD 0.022 Tw (nun ya\337la birlikte azald\335\333\335, erken okul \215a\333\335nda o\333lanlar-)Tj 0 -1.3 TD 0.105 Tw (da daha y\237ksek olup adelosan ya\337larda cinsiyetler ara-)Tj T* 0.07 Tw (s\335nda fark\335n azald\335\333\335, % 1-2\325sinde ge\215 adelosan ya\337lara)Tj T* 0.023 Tw (kadar devam edebilece\333i y\232n\237ndedir )Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 463.6628 672.6611 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw ((2))Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 472.987 670.021 Tm 0 Tr 0 0 0 1 k -0.0001 Tc (.)Tj 0.5228 0 Td 0 Tc 0.023 Tw (\206lkemizde ya-)Tj -16.5404 -1.3 TD 0.12 Tw (p\335lan \215al\335\337malar, en\237rezis nokt\237rna prevelans\335n\335 yakla-)Tj T* 0.012 Tc 0.113 Tw (\337\335k % 13.7 olarak g\232stermi\337tir )Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 444.9547 646.6611 Tm 0 Tr 0 0 0 1 k 0.012 Tc 0 Tw ((3))Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 454.5699 644.0211 Tm 0 Tr 0 0 0 1 k 0.012 Tc (.)Tj 0.63694 0 Td 0.113 Tw (T\237rk \215ocuklar\335nda)Tj -14.81283 -1.3 TD 0 Tc 0.12 Tw (idrar kontrol ya\337\335n\335n ortalama 2.9 ya\337 oldu\333u ve ya\337ta)Tj T* 0 Tw (art\335\337la birlikte s\335kl\335\333\335n azald\335\333\335 bildirilmektedir )Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 503.0307 620.6611 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw ((3-4))Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 519.0171 618.021 Tm 0 Tr 0 0 0 1 k 0 Tc (.)Tj -20.62061 -2.6 TD 0.113 Tw (En\237rezis nokt\237rna; \215ocuk ve ailesi i\215in olduk\215a s\335k\335nt\335)Tj 0 -1.3 TD 0.003 Tc 0.122 Tw (verici bir durum olup, tedavisi hekim, \215ocuk ve ailesi)Tj T* 0.002 Tc (taraf\335ndan ortakla\337a y\237r\237t\237lmelidir. Tedavisinde uyan-)Tj T* 0 Tc 0.063 Tw (d\335rma, s\335v\335 k\335s\335tlamas\335, kuru gecelerin \232d\237llendirilmesi,)Tj T* 0.025 Tw (psikoterapi, hipnoz, akupunktur ve ila\215 kullan\335lmas\335 yer)Tj 0 -1.30001 TD 0.002 Tc 0 Tw (almaktad\335r )Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 359.4913 529.6611 Tm 0 Tr 0 0 0 1 k 0.001 Tc 0 Tw ((5))Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 368.8573 527.0211 Tm 0 Tr 0 0 0 1 k 0.0016 Tc (.)Tj 0.62656 0 Td 0.002 Tc 0.123 Tw (Bunlar\335n i\215inde en\237rezis alarm\335, mono-)Tj -6.23119 -1.3 TD (semptomatik en\237rezis nokt\237rna tedavisinde hi\215 \337\237phe-)Tj 0 -1.30001 TD 0 Tc 0.072 Tw (siz en etkili yoldur )Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 392.8826 503.6611 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw ((2))Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 405.4242 501.0211 Tm 0 Tr 0 0 0 1 k 0 Tc 0.072 Tw (ve en d\237\337\237k n\237ks oran\335na sahip)Tj 12.88309 0.00001 TD (-)Tj -22.14441 -1.30001 TD 0.104 Tw (tir. Ancak, uygulama g\237\215l\237\333\237, ailelerin tam bilgilendi-)Tj 0 -1.3 TD 0.023 Tc 0.102 Tw (rilememesi, doktor, hasta ve aile \237yelerinin zaman\335,)Tj T* 0 Tc 0.081 Tw (sabr\335 ve yak\335ndan takibini gerektirmesi ve tedavide s\237-)Tj T* 0.007 Tw (reklilik sa\333laman\335n zorlu\333u gibi nedenlerle doktorlar ta-)Tj T* 0.006 Tc 0.119 Tw (raf\335ndan az tercih edilmektedir. ABD\325de 1981 y\335l\335nda)Tj T* 0 Tc 0.109 Tw (446 doktor aras\335nda yap\335lan bir \215al\335\337ma, en\237rezis nok)Tj 22.1444 0 TD (-)Tj -22.1444 -1.3 TD 0.004 Tc 0.121 Tw (t\237rna tedavisinde medikasyonun % 28 oran\335nda tercih)Tj T* 0.007 Tc 0.117 Tw (edildi\333ini, ancak alarm y\232nteminin yaln\335zca % 3 ora-)Tj T* 0.02 Tc 0.105 Tw (n\335nda kullan\335ld\335\333\335n\335 g\232stermi\337tir )Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 454.1035 386.6611 Tm 0 Tr 0 0 0 1 k 0.02 Tc 0 Tw ((1))Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 463.9058 384.0211 Tm 0 Tr 0 0 0 1 k 0.0198 Tc (.)Tj 0.64474 0 Td 0.02 Tc 0.105 Tw (\206lkemizde yeni)Tj -15.75422 -1.3 TD 0 Tc 0.019 Tw (yap\335lan bir \215al\335\337mada akupunktur ile 6 ayl\335k tedavide %)Tj T* 0.034 Tc 0.091 Tw (86 oran\335nda ba\337ar\335 g\232zlenerek, alternatif bir tedavi)Tj T* 0 Tc 0 Tw (olarak \232nerilmektedir )Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 401.6562 347.6611 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw ((6))Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 410.9804 345.0211 Tm 0 Tr 0 0 0 1 k 0 Tc (.)Tj -9.81694 -2.6 TD 0.004 Tc 0.121 Tw (\334la\215 tedavileri aras\335nda trisiklik antideprasanlar (TSA))Tj 0 -1.3 TD 0.007 Tc 0.118 Tw (ve desmopressin uygulamas\335 yer al\335r. \334mipiramin gibi)Tj T* 0 Tc 0.044 Tw (TSA\325lar genel olarak nokt\237rnal en\237rezis tedavisinde ilk)Tj T* 0.009 Tc 0.116 Tw (\232nerilen ila\215 de\333ildir. Potansiyel \232l\237mc\237l yan etkileri)Tj T* 0 Tc 0.02 Tw (ve bildirilen % 17 gibi d\237\337\237k uzun d\232nem iyile\337me ora-)Tj T* 0 Tw (n\335 )Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 323.4052 256.6611 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw ((7))Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 332.7294 254.021 Tm 0 Tr 0 0 0 1 k -0.0001 Tc (,)Tj 0.53136 0 Td 0 Tc 0.032 Tw (imipiramin kullan\335m\335n\335 ciddi olarak s\335n\335rlamakta-)Tj -2.5232 -1.3 TD 0.097 Tw (d\335r. En\237rezis nokt\237rna tedavisinde antimuskarinik ila\215-)Tj T* 0.002 Tc 0.123 Tw (lar da detrussor a\337\335r\335 aktivitesinin bir rol oynad\335\333\335 d\237-)Tj T* 0.018 Tc 0.107 Tw (\337\237n\237lerek denenmi\337, ancak etkileri konusunda klinik)Tj T* 0 Tc 0.036 Tw (kan\335tlar bulunamam\335\337t\335r )Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 411.8428 204.6611 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw ((2))Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 421.1671 202.021 Tm 0 Tr 0 0 0 1 k -0.0001 Tc (.)Tj 0.53628 0 Td 0 Tc 0.036 Tw (Oysa, plasebo kontroll\237 \215a-)Tj -11.37189 -1.3 TD 0.045 Tw (l\335\337malarda en\237rezis nokt\237rna tedavisinde desmopressin,)Tj T* 0.018 Tw (plaseboya g\232re daha etkili bulunmu\337 ve \215ocuklar\335n yak-)Tj T* 0.045 Tw (la\337\335k % 60\325\335 ilaca yan\335t vermi\337lerdir )Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 461.5505 165.6612 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw ((2))Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 10 0 0 10 470.8747 163.021 Tm 0 Tr 0 0 0 1 k -0.0001 Tc (.)Tj 0.54461 0 Td 0 Tc 0.045 Tw (Bizim \215al\335\337ma-)Tj -16.35098 -1.3 TD 0.013 Tc 0.111 Tw (m\335zda da bu g\232r\237\337\237 destekler nitelikte her iki grupta)Tj T* 0 Tc 0 Tw (ortalama % 60 yan\335t g\232zlendi.)Tj ET 0 0 0 0 k 56.693 324.851 226.772 16.48 re f Q /GS3 gs /GS2 gs q BT /F0 1 Tf 8 0 0 8 57.693 334.3643 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (Tablo 1. Hastalar\335m\335z\335n ya\337, cins ve tedavi \232zellikleri.)Tj ET 0 J 0 j 10 M []0 d 1 w 0 0 0 1 K 56.693 324.347 m 283.465 324.347 l S 0 0 0 0 k 56.693 250.0401 53.37 70.582 re f Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 57.6929 295.3587 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (Hasta say\335s\335 (n))Tj 0 -1.125 TD (Ya\337 (y\335l))Tj T* (Cins)Tj T* (Doz (\265g))Tj T* (S\237re (ay))Tj ET 0 0 0 0 k 122.031 250.0401 59.378 70.582 re f Q /GS3 gs /GS2 gs q BT /F0 1 Tf 8 0 0 8 139.8306 313.3587 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (Grup I)Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 147.7203 295.3587 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (30)Tj -1.03199 -1.125 TD (9.2\2613.5)Tj -1.88354 -1.125 TD (14 K\335z, 16 Erkek)Tj 2.29052 -1.125 TD (40 \265g)Tj 0.875 -1.125 TD (1)Tj ET 0 0 0 0 k 262.764 250.0401 20.701 70.582 re f BT /F3 1 Tf 8 0 0 8 271.1142 313.3587 Tm 0 0 0 1 k (p)Tj -0.90699 -2.25 TD (>0.05)Tj 0 -1.125 TD (>0.05)Tj T* (>0.05)Tj T* (<0.05)Tj T* (<0.05)Tj ET 0 0 0 0 k 56.693 210.4811 226.772 23.48 re f Q /GS3 gs /GS2 gs q BT /F0 1 Tf 8 0 0 8 57.6931 226.9945 Tm 0 Tr 0 0 0 1 k 0.005 Tc 0.12 Tw (Tablo 2. Gruplar aras\335ndaki tedavi sonu\215lar\335m\335z\335n kar\337\335la\337t\335r\335l-)Tj 0 -1.125 TD 0 Tc 0 Tw (mas\335.)Tj ET 0 J 0 j 10 M []0 d 1 w 0 0 0 1 K 56.693 209.977 m 283.465 209.977 l S 0 0 0 0 k 56.693 119.5511 102.047 87.591 re f BT /F0 1 Tf 8 0 0 8 57.6929 181.8783 Tm 0 0 0 1 k (Tedavi \232ncesi)Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 57.6929 172.8783 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (Yatak \335slatma say\335s\335 (n/2 hafta))Tj ET Q /GS3 gs /GS2 gs q BT /F0 1 Tf 8 0 0 8 57.6929 163.8783 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (Tedavi sonras\335)Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 57.6929 154.8783 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (Yatak \335slatma say\335s\335 (n/2 hafta))Tj 0 -1.125 TD (Cevap verme oran\335)Tj ET Q /GS3 gs /GS2 gs q BT /F0 1 Tf 8 0 0 8 57.6929 136.8783 Tm 0 Tr 0 0 0 1 k 0 Tc 0 Tw (Tedavi kesimi sonras)Tj ET Q /GS3 gs /GS2 gs q BT /F3 1 Tf 8 0 0 8 129.6871 136.8783 Tm 0 Tr 0 0 0 1 k 0 Tc